David Arons is the Chief Executive Officer of the National Brain Tumor Society. He previously served in leadership and external positions at the American Cancer Society in Minnesota, the Center for Lobbying in the Public Interest and at Independent Sector. As an attorney, he previously represented patients facing disabilities and serious health conditions. He is the author of several books, including Power in Policy: A Funder’s Guide to Advocacy and Civic Participation, Strengthening Nonprofit Advocacy, and A Voice for Nonprofits. He serves on the National Cancer Institute’s Council of Research Advocates and Clinical Trials Advisory Committee. In 2016, Mr. Arons was named to the Blue Ribbon Panel of experts selected to help advise the National Cancer Moonshot, led by former Vice President Joseph Biden.

Emy Chen, PhD, is Senior Director of Licensing at the Robert and Renée Belfer Office for Dana-Farber Innovations (BODFI). In this role, she has oversight over the Innovations Licensing team as a whole. A primary focus for her will be to further refine and optimize the team's ability to provide excellent partnership and collaboration both with clinicians and research scientists at Dana-Farber and with external stakeholders in industry. Prior to joining BODFI, Emy was most recently a Director of Licensing at Partners HealthCare Innovation, where she spent 13 years supporting investigators and building relationships with biotech and pharma companies, primarily for innovators in the disciplines of Medicine, Neuroscience and Dermatology. Emy holds a PhD from Harvard University in Molecular and Cellular Biology, a BA from University of California, Berkeley in Molecular and Cell Biology, and is a registered patent agent with the United States Patent and Trademark Office (USPTO).

Before joining the T1D Fund in 2017, Peter Lomedico spent 11 years working with JDRF Research to establish T1D research collaborations with biotechnology and pharmaceutical companies. Peter has a diverse background in molecular biology, diabetes research and drug discovery, before JDRF he worked at several biotechnology companies (NeoGenesis, CuraGen and Genome Therapeutics) and ran drug discovery and development projects at Hoffmann-La Roche in NJ and Switzerland. Early in his career, Peter conducted diabetes research as a grad student and was a JDRF postdoctoral fellow at Harvard University. He has more than 30 publications and three issued patents. Peter serves on the board for AnTolRx, Inc., a T1D Immunology Company spun off from Harvard Medical School with a JDRF equity investment. Peter has a Ph.D. in molecular biology from the University of Texas Health Science Center at Houston and a B.S. in biology from Villanova University.

Andrea has focused on partnering early stage life sciences technologies for over 15 years. Since 2008 she has been at Cancer Research UK - Boston, building relationships between Cancer Research UK and the biotech/pharma industry throughout the US. Prior to CRUK, Andrea was at MIT's Technology Licensing Office, where she engaged with both established and startup companies to license technology from MIT, the Whitehead Institute and Lincoln Laboratory. Previous to that, Andrea was one of the early employees at Variagenics, a personalized medicine startup out of MIT. Initially hired as a scientist, after three years Andrea transitioned into business development, where she spent a further three years focused on alliance development in the US and Europe, until the company was acquired. Andrea received her undergraduate degree in Biology at MIT and her PhD from Harvard, followed by a postdoctoral fellowship in Genetics Institute's Small Molecule Drug Discovery group.

Dr. Frances Toneguzzo is Head of Intellectual Property at Life Biosciences. She leads with an extensive skill set in technology evaluation, business development, and licensing. Dr. Toneguzzo has a background in negotiating deals with life sciences companies, and is a strategic thinker and driver of new initiatives designed to stimulate, support and sustain innovation. She previously served as Executive Director at Partners Healthcare, Harvard University, and Tufts University. She is also seasoned in the financing and management of startup companies, co-founding the biotech company Dyrnamix Inc. She received her PhD in biochemistry from McMaster University.